This Study Aims to Find and Test a Safe Dose of BI 905677 in Patients With Different Types of Cancer (Solid Tumours)

PHASE1TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 8, 2018

Primary Completion Date

July 27, 2022

Study Completion Date

July 27, 2022

Conditions

Neoplasms

Interventions

DRUG

BI 905677

Solution for infusion

Trial Locations (5)

Memorial Sloan-Kettering Cancer Center, New York

University of Southern California, Los Angeles

National Cancer Center Hospital East, Chiba, Kashiwa

Erasmus MC Kanker Instituut, Rotterdam

Hospital Vall d'Hebron, Barcelona